DXRX logo
Lab Alerts

Catch-up on the series: HER2 Testing in Breast Cancer

17 Jul 2024

This content is organized and funded by AstraZeneca. This content is intended for healthcare professionals only. Z4-62779. DOP July 2024.

AZ Logo

Over the past 6 months, Diaceutics have delivered a series of digital activities focused on the new and emerging perspectives on the classification of HER2 in breast cancer.

Our aim is to raise awareness of the new perspectives emerging on HER2 testing and expression, particularly in relation to recognizing low levels of HER2 in breast cancer patients.

Catch-up on the activities in this series to:

  • Learn about the importance of recognizing HER2 low and HER2 negative patients and how this can be implemented in your lab
  • Listen to Key Opinion Leader, Professor Dr Abeer Shaaban, discuss her perspective on HER2 expression during the Lab Talk, A new perspective on HER2 testing- Evolving the lab practices to match clinical advances
  • Access the HER2 Report Checklist from the series and share with colleagues or print and display in your labs for ease of reference

In the first Lab Alert, we highlighted that up to 60% of breast cancers classed as HER2 negative have detectable levels of HER2 expression1. This has created a need for a consistent assessment standard that recognizes HER2 biomarker expression as a spectrum of negative, low and positive, encouraging labs to re-think what they know about determining HER2 expression and how this can impact patients.

This was followed by a Lab Talk with Professor Dr Abeer Shaaban MSc, PhD, FRCPath. During this session, Prof. Dr Shaaban discussed the clinical utility of HER2 testing, HER2 scoring and the spectrum of expression and the technical factors to be considered, including analytical and pre-analytical. Click here to watch the recording and learn more.

Interested in a deep dive into HER2 testing pre-analytical and analytical considerations? Register interest and provide comments to help inform future articles and events.
Register interest

1. Schettini F, et al. NPJ Breast Cancer. 2021;7:1-13.